Results 71 to 80 of about 581 (108)

Real-world safety profile of sonidegib: a disproportionality analysis based on the FDA adverse event reporting system

Frontiers in Oncology
BackgroundSonidegib is a novel treatment for locally advanced basal cell carcinoma (LaBCC) with demonstrated efficacy and safety in clinical trials. However, its real-world safety profile remains insufficiently characterized. This study aimed to evaluate
Kaidi Zhao, Qinxiao Li, Miao Qin, Shengxiang Xiao, Jing Li, Jiashu Liu   +5 more
doaj   +1 more source

Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer

Cells, 2019
The Hedgehog/GLI signaling pathway plays an important role in normal embryonic tissue development and has been implicated in the pathogenesis of various human cancers.
Hao Xie, Brooke D. Paradise, Wen Wee Ma, Martin E. Fernandez-Zapico   +3 more
doaj   +1 more source

Real-Life Experience with Sonidegib for Locally Advanced Basosquamous Carcinoma: A Case Series

Case Reports in Dermatology
Introduction: Basosquamous carcinoma is an uncommon subtype of basal cell carcinoma (BCC), characterized by aggressive local growth and metastatic potential, that mainly develops on the nose, perinasal area, and ears, representing 1.2–2.7% of all head ...
Enrico Bocchino, Simone Cappilli, Gerardo Palmisano, Andrea Paradisi, Alfredo Piccerillo, Alessandro Di Stefani, Ketty Peris   +6 more
doaj   +1 more source

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.

PLoS ONE
Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50-60% response rate.
Shivani Patel, Heather Armbruster, Gretchen Pardo, Brianna Archambeau, Na Hyun Kim, Joanne Jeter, Richard Wu, Kari Kendra, Carlo M Contreras, Natalie Spaccarelli, Brittany Dulmage, Llana Pootrakul, David R Carr, Claire Verschraegen   +13 more
doaj   +1 more source

Switch to every-other-day sonidegib dose reduction schedule in advanced basal cell carcinoma: a multicenter retrospective observational study on effectiveness and safety

Background: Sonidegib displays class-specific adverse events (AEs), which impair therapeutic adherence. Every-other-day administration is within the label of sonidegib approval.
Peris K., Villani A., Di Stefani A., Fargnoli M. C., Mannino M., Dika E., Queirolo P., Bianchi L., De Giorgi V., Quaglino P., Bocchino E., Palla M., Lacarrubba F., Scalvenzi M., Longo C., Argenziano G., Costa C., Pellacani G., Maione V., Ascierto P. A., Zalaudek I.   +20 more
core   +1 more source

A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients

, 2017
Sonidegib (Odomzo®) is an orally available Smoothened inhibitor for the treatment of advanced basal cell carcinoma. Sonidegib was found to be metabolized primarily by cytochrome P450 (CYP)3A in vitro.
Rebello, Sam, Won, Christina, Einolf, Heidi, Zhou, Jocelyn, Wang, Lai   +4 more
core   +1 more source

Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib–Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management

Pharmaceuticals
Background/Objectives: Basal cell skin cancer (BCSC) develops when skin cells proliferate uncontrollably. Sonidegib (SDB) is a therapeutic option for the treatment of BCSC by inhibiting hedgehog signaling.
Maha M. Ghalwash, Amr Gamal Fouad, Nada H. Mohammed, Marwa M. Nagib, Sherif Faysal Abdelfattah Khalil, Amany Belal, Samar F. Miski, Nisreen Khalid Aref Albezrah, Amani Elsayed, Ahmed H. E. Hassan, Eun Joo Roh, Shaimaa El-Housiny   +11 more
doaj   +1 more source

Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study

Frontiers in Medicine
Gorlin-Goltz syndrome (nevoid basal cell carcinoma syndrome) is a rare autosomal dominant tumor-predisposition disorder characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, and variable systemic manifestations ...
Linli Liu, Heng Du, Neng Wang, Shuang Lv, Chunshui Yu, Lingli Deng   +5 more
doaj   +1 more source

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial

Clinical, Cosmetic and Investigational Dermatology, 2020
John T Lear,1 Axel Hauschild,2 Eggert Stockfleth,3 Nicholas Squittieri,4 Nicole Basset-Seguin,5 Reinhard Dummer6 1Manchester Royal Infirmary, Manchester, UK; 2Klinik Für Dermatologie, Venerologie Und Allergologie Universitätsklinikum Schleswig ...
Lear JT, Hauschild A, Stockfleth E, Squittieri N, Basset-Seguin N, Dummer R   +5 more
doaj  

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

, 2014
PURPOSE: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor ...
D Mahalingam (7806581), Y Shou (7806584), MA Moles (7806587), CP Turtschi (7806572), AC Mita (7806605), DD Amakye (7806599), KL Rose (7806596), J Rodon (7806563), RG Stoller (7806569), J Sarantopoulos (7806578), HA Tawbi (7806566), L Yang (6502793), R Dummer (7806602), J Baselga (7806575), C Granvil (7806590), AL Thomas (7661462), E Hurh (7806593)   +16 more
core   +2 more sources